SANOFI-AVENTIS U S

This study was a single-center, randomized, double-blind, 3-treatment, 3-period, 6-sequence, crossover, euglycemic clamp study. Adult patients (N=30) with type 1 diabetes were randomized to receive 0.3 U/kg dose of either ADMELOG or Comparator (Humalog, or a non-US-approved insulin lispro, 100 Units/mL) under fasted conditions. The pharmacokinetic and pharmacodynamic profiles were evaluated over 12 hours. 1,3... The time course of action of insulin and insulin analogs, including insulin lispro products, may vary considerably in different individuals or within the same individual. The rate of insulin absorption and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables.

Also known as: sanofi-aventis U.S. LLC